PPA
JNCE

Parametric Portfolio Associates’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Parametric Portfolio Associates’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$101K Buy
14,942
+24
+0.2% +$171 ﹤0.01% 3560
2021
Q4 		$125K Buy
14,918
+546
+4% +$4.5K ﹤0.01% 3520
2021
Q3 		$107K Buy
14,372
+2,793
+24% +$17.3K ﹤0.01% 3528
2021
Q2 		$79K Sell
11,579
-208
-2% -$1.73K ﹤0.01% 3506
2021
Q1 		$121K Sell
11,787
-473
-4% -$5.18K ﹤0.01% 3951
2020
Q4 		$86K Sell
12,260
-1,014
-8% -$7.89K ﹤0.01% 3898
2020
Q3 		$108K Sell
13,274
-19,201
-59% -$119K ﹤0.01% 3782
2020
Q2 		$224K Buy
32,475
+15,497
+91% +$83.6K ﹤0.01% 3593
2020
Q1 		$81K Sell
16,978
-1,626
-9% -$9.36K ﹤0.01% 3764
2019
Q4 		$162K Sell
18,604
-2,158
-10% -$11.7K ﹤0.01% 3782
2019
Q3 		$69K Buy
20,762
+1,915
+10% +$7.67K ﹤0.01% 3877
2019
Q2 		$93K Sell
18,847
-2,417
-11% -$12.8K ﹤0.01% 3850
2019
Q1 		$132K Buy
21,264
+9,488
+81% +$45.8K ﹤0.01% 3778
2018
Q4 		$40K Buy
+11,776
New +$55K ﹤0.01% 3864
2018
Q3 		– Sell
-46,230
Closed -$354K – 3980
2018
Q2 		$354K Buy
+46,230
New +$667K ﹤0.01% 3492

Other funds holding JNCE

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Parametric Portfolio Associates's JNCE Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Jounce Therapeutics, Inc. Common Stock (JNCE) stake by 0.16% in Q1 2022, buying an estimated $171 and bringing the position to 14,942 shares worth $101K. The position accounts for ﹤0.01% of the portfolio, ranked #3560.

Parametric Portfolio Associates first reported a position in JNCE in Q2 2018 and has held it in 15 quarters since. The position peaked at $354K in Q2 2018. 113 funds tracked by Wall St. Rank hold JNCE as of Q1 2022.

  • Parametric Portfolio Associates held 14,942 shares of Jounce Therapeutics, Inc. Common Stock worth $101K as of Q1 2022.
  • Parametric Portfolio Associates bought 24 Jounce Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $171.
  • Jounce Therapeutics, Inc. Common Stock made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3560 holding.
  • Parametric Portfolio Associates first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2018 and has held it in 15 quarters since.
  • Parametric Portfolio Associates's Jounce Therapeutics, Inc. Common Stock position peaked at $354K in Q2 2018.
  • 113 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.